This study analyzed patients diagnosed with MET-amplified GC or GC with PLC at any time point of the disease course from 2011 to 2021 in two centers. Clinicopathological features and survival outcomes of MET-amplified GC were analyzed. The clinical and molecular implications of GC with PLC were discussed.
Fifty-eight patients with MET-amplified GC and 20 patients with GC accompanied by PLC were finally enrolled for analysis (including 13 overlapped patients). GC with PLC was more common in female patients (p = 0.010), diagnosed at a younger age (p = 0.002), presented with a higher baseline ECOG PS (p = 0.016), and was more likely to develop lung metastasis (p < 0.001), and serous effusion (p = 0.026) than GC without PLC. Patients with primary MET-amplified GC had a worse prognosis than those with secondary MET-amplified GC (p = 0.005). The application of anti-MET therapy was associated with numerically prolonged survival, but the association was not statistically significant (p = 0.07). MET amplification was concentrated in patients with PLC, in which anti-MET therapies elicited a high response rate.
MET-targeted therapies are efficacious in real-world populations with MET-amplified GC. Patients with PLC have distinct clinical and molecular features and might benefit from MET-targeted therapies.
方法:本研究分析了两个中心在2011年至2021年病程的任何时间点诊断为MET扩增的GC或具有PLC的GC的患者。分析MET扩增GC的临床病理特征和生存结果。讨论了GC与PLC的临床和分子意义。
结果:最终纳入58例MET扩增GC患者和20例GC伴PLC患者(包括13例重叠患者)进行分析。GC合并PLC在女性患者中更为常见(p=0.010),诊断为年轻(p=0.002),呈现较高的基线ECOGPS(p=0.016),并且更容易发生肺转移(p<0.001),浆液性积液(p=0.026)高于无PLC的GC。原发性MET扩增的GC患者的预后比继发性MET扩增的GC患者差(p=0.005)。抗MET治疗的应用与数字上延长的生存期相关,但相关性无统计学意义(p=0.07).MET扩增集中在PLC患者中,其中抗MET疗法引起高反应率。
结论:MET靶向治疗在MET扩增GC的真实世界人群中是有效的。PLC患者具有不同的临床和分子特征,可能受益于MET靶向治疗。